Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

S. Rugo, Hope; Im, Seock‐Ah; Cardoso, Fátima; Cortés, Javier; Curigliano, Giuseppe; Musolino, Antonino; D. Pegram, Mark; S. Wright, Gail; Saura, Cristina; Escrivá-de-Romaní, Santiago; De Laurentiis, Michelino; Lévy, Christelle; Brown‐Glaberman, Ursa; Ferrero, Jean-­Marc; de Boer, Maaike; Kim, Sung‐Bae; Petráková, Katarína; A. Yardley, Denise; Freedman, Orit; Jakobsen, Erik; Kaufman, Bella; Yerushalmi, Rinat; A. Fasching, Peter; L. Nordstrom, Jeffrey; Bonvini, Ezio; Koenig, Scott; Edlich, Sutton; Hong, Shengyan; P. Rock, Edwin; J. Gradishar, William; Study Group, SOPHIA

doi:10.1001/jamaoncol.2020.7932

Public

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

Published in JAMA Oncology • Jan 23, 2021

Authors:

Hope S. Rugo

Seock‐Ah Im

Fátima Cardoso

Abstract

IMPORTANCE: ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune act...

Subject

Medicine

Trastuzumab

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!